Product image of Latira (Timolol Maleate, Latanoprost) supplied by GNH India

Latira

Active Ingredient:
Timolol Maleate, Latanoprost
Origin:
EU

Latira (Timolol Maleate, Latanoprost)

Timolol maleate and latanoprost, the active ingredients in Latira, are a beta‑blocker and prostaglandin analog presented as eye drops for ocular use. They treat open‑angle glaucoma and ocular hypertension in adult patients by lowering intraocular pressure.

GNH India supplies Latira as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to European Union quality standards and provides reliable global distribution for this prescription ophthalmic solution. Our network ensures timely delivery and regulatory compliance across multiple regions.

Manufacturer / TM Owner

Ratiopharm Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Latira is used in the management of ocular conditions that involve elevated intraocular pressure.
  • Open‑angle glaucoma: reduces intraocular pressure to protect the optic nerve and preserve visual field.
  • Ocular hypertension: lowers intraocular pressure to prevent progression to glaucoma.
  • Secondary glaucoma (e.g., pseudoexfoliative): helps control intraocular pressure when other therapies are insufficient.

How It Works

  • Timolol maleate acts as a non‑selective beta‑adrenergic antagonist, decreasing aqueous humor production by blocking β1 and β2 receptors in the ciliary body. Latanoprost is a prostaglandin F2α analog that binds to FP receptors in the iris‑ciliary body, enhancing uveoscleral outflow of aqueous humor. The combined actions lower intraocular pressure more effectively than either component alone.

Side Effects

The ocular formulation of Latira may cause a range of local and systemic adverse reactions.

Common Side Effects

  • Blurred vision: transient visual disturbance after instillation.
  • Eye irritation or burning: mild discomfort at the site.
  • Conjunctival hyperemia: redness of the eye.
  • Increased eyelash growth: longer, thicker lashes.
  • Darkening of iris pigmentation: gradual brown discoloration.

Serious or Rare Side Effects

  • Severe allergic reaction: swelling, itching, or rash requiring medical attention.
  • Systemic beta‑blocker effects: bradycardia, hypotension, bronchospasm in susceptible patients.
  • Corneal edema or ulceration: persistent pain or vision loss needing urgent care.

Precautions & Warnings

Before prescribing Latira, clinicians should consider several safety and handling precautions.

  • Pregnancy: safety not established; use only if potential benefit justifies risk.
  • Breastfeeding: unknown excretion; evaluate risk versus benefit.
  • Contraindications: asthma, severe chronic obstructive pulmonary disease, bradycardia, second‑ or third‑degree heart block.
  • Systemic beta‑blocker therapy: monitor for additive cardiovascular depression.
  • Contact lens wearers: remove lenses before instillation to avoid discomfort.
  • Store at room temperature below 25 °C: keep in original container, protect from light and moisture.

Avoid Interactions

Latira can interact with other systemic or ocular agents, requiring careful medication review.

Major Interactions (Avoid)

  • Other non‑selective beta‑blockers: may cause excessive bradycardia or hypotension.
  • Systemic antihypertensives (e.g., calcium channel blockers): increased risk of cardiovascular depression.
  • Epinephrine eye drops: antagonistic effect reducing efficacy of latanoprost.

Moderate Interactions (Monitor Closely)

  • Topical NSAIDs: may increase risk of corneal complications.
  • Other prostaglandin analogs: additive ocular side effects such as iris pigmentation.
  • Systemic carbonic anhydrase inhibitors: enhanced intraocular pressure lowering effect, monitor pressure.

Frequently Asked Questions

Latira is a prescription ophthalmic solution indicated for the treatment of open‑angle glaucoma and ocular hypertension. By lowering intraocular pressure, it helps prevent optic nerve damage and preserves visual function in adult patients.

Timolol maleate reduces aqueous humor production through non‑selective beta‑adrenergic blockade, while latanoprost, a prostaglandin F2α analog, increases uveoscleral outflow of aqueous humor. The combined effect results in a greater reduction of intraocular pressure than either component alone.

The dosing regimen for Latira is determined by the prescribing clinician based on the patient’s condition and response. Typically, one drop is instilled in the affected eye(s) once daily, but the exact schedule should follow the prescriber’s instructions.

Safety data for Latira in pregnancy and lactation are limited. It should be used only if the potential benefit outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To order Latira, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Latira combines a beta‑blocker (timolol) and a prostaglandin analog (latanoprost) in a single eye‑drop formulation, offering greater intraocular pressure reduction than monotherapy with either agent. This dual‑action approach can simplify treatment regimens compared with using separate products.

Latira eye drops should be stored at room temperature below 25 °C, in the original container, protected from light and moisture. Do not freeze the product, and keep it out of reach of children.

Instill one drop into the affected eye(s) as directed by the prescriber, usually once daily. Wash hands before use, avoid touching the dropper tip to the eye or any surface, and close the eye gently after administration.

Serious adverse events include severe allergic reactions, systemic beta‑blocker effects such as bradycardia or bronchospasm, and ocular complications like corneal edema or ulceration. Patients should seek immediate medical attention if they experience these symptoms.

Latira is contraindicated in patients with known hypersensitivity to timolol, latanoprost, or any excipients, as well as those with asthma, severe COPD, bradycardia, or second‑ or third‑degree heart block. Caution is also advised for individuals using other beta‑blockers.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Timolol Maleate, Latanoprost

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT